688068 Beijing Hotgen Biotech Co.,LtdWatchlist
About Beijing Hotgen Biotech Co.,Ltd Company
The company, founded in June 2005, is a high-tech biotechnology enterprise with the mission of “developing biotechnology to benefit human health”. The company continues to explore independent innovative diagnostic technology platforms, actively develop and expand liquid biopsy cancer early screening technology, and establish a multiomics diagnostic technology platform including protein markers, sugar chain exosomes, and DNA methylation; at the same time, it has set up a future technology research institute to explore cutting-edge technology, actively lay out biopharmaceutical fields such as antibody drugs, live bacteria drugs, and exosome drugs, and create a development strategy for the entire industry chain from diagnosis to treatment. The company is a high-tech biotechnology enterprise with the mission of “developing biotechnology to benefit human health”. It closely focuses on innovative biotechnology and lays out solutions from early screening and diagnosis to treatment of diseases. Main products: In vitro diagnostic products, antibody drugs, active bacteria drugs, nucleic acid drugs, etc. Corporate honors: National Technological Invention Award, Rare Earth Science and Technology Award, Independent Innovation Gold Award, etc.
Hot Scenery Biology (688068.SH): Plans to raise 3,0663,600 yuan in savings to permanently supplement working capital
Glonghui, September 13, 丨 Hot Scenery Biotech (688068.SH) announced that since the company's fund-raising investment project “12 million in vitro diagnostic reagents, 850 supporting instruments production base and R&D center project” has been completed and put into use, in line with actual business conditions, in order to improve the efficiency of the use of capital raised, the company plans to raise funds saved from this fund-raising investment project of 3,0063,600 yuan (including interest income. The actual transfer amount is based on the bank account balance on the day the funds were transferred out) to permanently supplement the working capital for the company's daily production and operation.
Hot Scenery Bio (688068.SH) released first-half results, net profit of 84.7687 million yuan, a year-on-year decrease of 89.60%
Hot Scenery Biology (688068.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
The main shareholder of Hot Jing Biotech (688068.SH) reduced their holdings by a total of 922,600 shares
According to the Zhitong Finance App, Hotjing Biotech (688068.SH) announced that Qingdao Tongcheng Hot Jing Enterprise Management Consulting Partnership (Limited Partnership) (“Tongcheng Hot Jing”), which holds more than 5% of the company's shares, has reduced its holdings by 922,600 shares, accounting for 1.00% of the total share capital. The number of holdings reduced in this holdings reduction plan is more than half.